Stockscreener 앱 받기
0.00
100.00%
-0.054
전일 마감가:
$0.054
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.072
52주 변동 폭
$0.00
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
명칭
Geovax Labs Inc
전화
678 384 7220
주소
1900 Lake Park Drive, Suite 380, Smyrna
GOVXW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc 주식(GOVXW)의 최신 뉴스
Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Drops By 12.3% - Defense World
GeoVax Labs CEO Makes Bold Stock Purchase! - TipRanks
Geovax labs CEO David Dodd acquires $10,800 in common stock - Investing.com India
Geovax Labs stock hits 52-week low at $1.09 amid market challenges - Investing.com
Roth Capital Forecasts GeoVax Labs FY2029 Earnings - Defense World
GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from D. Boral Capital - Defense World
GeoVax Labs Advances Vaccine Trials and Expands Operations - TipRanks
GeoVax Labs Earnings Call: Mixed Sentiments and Strategic Plans - TipRanks
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update - TradingView
Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Earnings call transcript: GeoVax Q4 2024 highlights ongoing challenges By Investing.com - Investing.com South Africa
GEOVAX LABS Earnings Results: $GOVX Reports Quarterly Earnings - Nasdaq
GeoVax Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: GeoVax Q4 2024 highlights ongoing challenges - Investing.com
What's Next: Geovax Labs's Earnings Preview - Benzinga
GEOVAX LABS Earnings Preview: Recent $GOVX Insider Trading, Hedge Fund Activity, and More - Nasdaq
GeoVax Labs IncEnters Placement Agency And Securities Purchase Agreements With A.G.P./Alliance Global PartnersSEC Filing - MarketScreener
GeoVax Labs Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
GeoVax Prepares to Announce Fourth Quarter and Full Year 2024 Financial Results - citybuzz -
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World
International - Financial Content
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK - Yahoo Finance
GeoVax CEO to Present at 37th Annual Roth Conference, Highlighting COVID-19 Vaccine and Cancer Therapy Research - citybuzz -
GeoVax to Present at the 37th Annual Roth Conference - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 35.5% in February - Defense World
News - Financial Content
Geovax Labs Inc (NASDAQ: GOVX) Could Fell Another -164.9% - Stocks Register
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Thursday - Defense World
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness - Yahoo Finance
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Rating of “Buy” from Analysts - Defense World
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health - Yahoo Finance
GeoVax shareholders approve warrant exercises - MSN
GeoVax to Highlight Mpox Vaccine Development at Emerging Growth Conference - citybuzz -
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award - Yahoo Finance
Was Geovax Labs Inc (GOVX)’s session last reading good? - US Post News
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs - Financial Content
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - citybuzz -
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
Geovax Labs Inc (GOVXW) 재무 분석
Geovax Labs Inc (GOVXW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):